Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Items 701–800 of 889
What's New on Alzheimer's Disease? Insights From AD Mouse Models
Rey, C. C., Cattaud, V., Rampon, C., & Verret, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11400-x · Cited by 6
Moss, D. E., Rodriguez, L. A., Herndon, W. C., Vincenti, S. P., & Camarena, M. L. (1986) · Advances in behavioral biology · doi:10.1007/978-1-4613-2179-8_62 · Cited by 6
Receptors in Human Brain Diseases: A use for Receptor Autoradiography in Neuropathology
Palacios, J. M., Cortés, R., Dietl, M., & Probst, A. (1988) · Journal of Receptor Research · doi:10.3109/10799898809049008 · Cited by 6
Differential responses of rat cerebral somatostatinergic and cholinergic cells to glutamate agonists
Ham, J., Duberley, R. M., RICKARDS, C. R., & Scanlon, M. F. (1993) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160172 · Cited by 6
“These include the loss of intrinsic somatostatinergic neurons in the frontoparietal and temporal cortex and the loss of cholinergic function in the cortical and hippocampal regions ( Davies et al., 1980; Whitehouse et al., 1982) The mechanism underlying the selective destruction of neurons is unknown; one possibility…”
BackgroundPascualy, M., Peskind, E. R., Wingerson, D. K., van Belle, G., Veith, R. C., Dorsa, D. M., & Raskind, M. A. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00026-7 · Cited by 6
Maeda, K., Kaneda, H., Whetsell, W. O., & Tamminga, C. A. (1997) · Neuroscience Research · doi:10.1016/s0168-0102(97)00102-8 · Cited by 6
Delfs, J. R., & Dichter, M. A. (1985) · Springer eBooks · doi:10.1007/978-1-4684-4961-7_14 · Cited by 6
A Mouse Model of Sporadic Alzheimer’s Disease with Elements of Major Depression
Бобкова, Н. В., Chuvakova, L. N., Kovalev, V. I., Zhdanova, D. Y., Chaplygina, A. V., Rezvykh, A. P., & Evgen’ev, M. B. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04346-7 · Cited by 6
“…changes in the expression of the genes responsible for the synthesis of peptide receptor ligands, which was manifested in a decrease in the expression of somatostatin receptor genes 1 and 4 ( Sstr1 and Sstr4 ) in the hippocampus, which represents an early pathological signature of AD [73, 74].”
High‐Level Expression and Efficient Purification of Recombinant Somatostatin in Escherichia Coli
Notani, J., Saitoh, Y., Terada, M., Yamada, H., Ishii, Y., Satoh, S., Tomoi, M., & Niwa, M. (1989) · Biotechnology Progress · doi:10.1002/btpr.5420050110 · Cited by 5
Fontanesi, G., Siciliano, R., Porciatti, V., & Bagnoli, P. (1996) · Visual Neuroscience · doi:10.1017/s0952523800007574 · Cited by 5
Neuropeptide Changes in Cortical and Deep Gray Structures in Alzheimer's Disease
Roeske, L. C., & Auchus, A. P. (1995) · Reviews in the Neurosciences · doi:10.1515/revneuro.1995.6.4.317 · Cited by 6
Kawahata, K., Xu, H., Takahashi, M., Murata, K., Han, W., Yamaguchi, Y., Fujii, A., Yamaguchi, K., & Yamakuni, T. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.10.006 · Cited by 6
Neurotransmitter Receptors in Human Brain Diseases
Probst, A., Mengod, G., & Palacios, J. M. (1991) · Current topics in pathology · doi:10.1007/978-3-642-75515-6_9 · Cited by 5
Martinez-Ferrer, A., Boyano-Adánez, M. D. C., Izquierdo-Claros, R. M., & Arilla, E. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00095-6 · Cited by 5
“In addition, it has been demonstrated that the brain somatostatinergic system is one of the most severely affected systems in patients with Alzheimer’s disease, suggesting its possible involvement in alterations of memory capacity of these patients (Davies et al. 1980).”
BackgroundGulya, K., Szikra, J., & Kása, P. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00575-p · Cited by 5
Fukami, S., Iwata, N., & Saido, T. C. (2002) · Drug Development Research · doi:10.1002/ddr.10073 · Cited by 7
“Therefore, the decrease in some of the neuropeptides, such as somatostatin in sporadic AD brains [Davies et al., 1980; Schindler et al., 1996], may be closely associated with Ab deposition through the downregulation of neprilysin expression.”
Ohbu, S., Yoshioka, N., HONDA, M., Andoh, Y., Sato, Y., Takao, N., Fukuda, H., & Wakayama, Y. (1995) · Internal Medicine · doi:10.2169/internalmedicine.34.148 · Cited by 5
Cutler, N. R., & Narang, P. K. (1985) · Geriatric Nursing · doi:10.1016/s0197-4572(85)80031-8 · Cited by 6
Trophic Factors in Brain Aging and Disease
Appel, S. H., Ojika, K., Tomozawa, Y., & Bostwick, J. R. (1985) · Advances in applied neurological sciences · doi:10.1007/978-3-642-70644-8_18 · Cited by 5
Miyasaka, K., Tateishi, K., Tomita, H., Sazaki, N., Okubo, K., Matsumoto, M., & Funakoshi, A. (1993) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(93)90027-f · Cited by 5
Dementia of the Alzheimer Type: An Oral and Biochemical Study1
de Périère, D. D., Sanchez, J., Bertrand, L., & González, L. (1987) · Gerodontology · doi:10.1111/j.1741-2358.1987.tb00292.x · Cited by 5
[40] Localization of somatostatin receptors
Pelletier, G., Leroux, P., & Morel, G. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)24042-2 · Cited by 5
Arendash, G. W., Sengstock, G. J., Shaw, G., & Millard, W. J. (1989) · Advances in behavioral biology · doi:10.1007/978-1-4684-5727-8_21 · Cited by 5
Sasaguri, H., Takamura, R., Watamura, N., Kakiya, N., Ohshima, T., Fujioka, R., Yamazaki, N., Sekiguchi, M., Iwata, K., Matsuba, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457281 · Cited by 6
Futácsi, A., Rusznák, K., Szarka, G., Völgyi, B., Wiborg, O., & Czéh, B. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1542229 · Cited by 6
Characterizing the expression profile of 3R tau pathology in Pick’s disease
Tamvaka, N., Soto‐Beasley, A. I., Gavrielatos, M., Heckman, M. G., Ren, Y., Udine, E., Quicksall, Z., Liskey, D., Castanedes‐Casey, M., Wszołek, Z. K., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt6105 · Cited by 5
“Previous studies have shown a similar decrease in SST expression in AD; however, these have been linked to amyloid deposition ( 29 ).”
Wang, F., Matsuoka, N., Mutoh, S., & Kaneko, S. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057687 · Cited by 4
Sekiguchi, H., Habuchi, C., Iritani, S., Arai, T., & Ozaki, N. (2009) · Psychogeriatrics · doi:10.1111/j.1479-8301.2009.00285.x · Cited by 4
Inhibitory effect of somatostatin on prostaglandin E2 synthesis by primary neonatal rat glial cells
Dror, N., Tveria, L., Meniv, I., Ben-Shmuel, S., Filipovich‐Rimon, T., & Fleisher‐Berkovich, S. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.06.005 · Cited by 5
The Pathogenesis of Alzheimer’s Disease. What Causes Dementia?
Terry, R. D. (1992) · Springer eBooks · doi:10.1007/978-3-642-46759-2_10 · Cited by 4
Self-citationMartínez, A., & Arilla, E. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90162-v · Cited by 4
Mitsuo, K., & Schwartz, J. P. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08900.x · Cited by 4
Mulcrone, J., & Whatley, S. A. (1993) · Psychological Medicine · doi:10.1017/s0033291700026301 · Cited by 4
“This molecular result correlates with previous immunological findings of the possible involvement of somatostatin in the neuropathology of AD (Davies et al. 1980; Beal et al. 1985).”
ResultFlorio, T., Magri, G., Landolfi, E., Meucci, O., GRIMALDI, M., Schettini, G., & Marino, A. (1988) · Pharmacological Research Communications · doi:10.1016/s0031-6989(88)80056-0 · Cited by 5
Is the inhibitory effect of somatostatin on the heart due to K+ channel activation?
Freeman, S. E., Lau, W., & Szı́lagyi, M. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90575-q · Cited by 4
Neurotransmitter and Neuropeptide Systems in Alzheimer-Type Dementia
Perry, E. K., & Perry, R. H. (1982) · Experimental brain research. Supplementum · doi:10.1007/978-3-642-68507-1_19 · Cited by 4
Lussier, I., & Stip, É. (1995) · Europe PMC (PubMed Central) · Cited by 4
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 4
Shang, T., Yang, S., Zhai, T., He, W., Mamourian, E., Zhang, J., Hou, B., Lee, J., Duong-Tran, D. A., Moore, J. H., et al. (2025) · Innovation in Aging · doi:10.1093/geroni/igaf102 · Cited by 3
Neurobiologische Aspekte psychischer Störungen bei degenerativen Hirnerkrankungen im Alter
Roth, M., & Mountjoy, C. Q. (1989) · Springer eBooks · doi:10.1007/978-3-642-71825-0_3 · Cited by 5
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 4
Chapter 7 Cerebral changes in alzheimer's disease
Plum, F. (1986) · Progress in brain research · doi:10.1016/s0079-6123(08)64602-6 · Cited by 3
Neural Basis of Hyposmia in Alzheimer’s Disease
Saiz‐Sánchez, D., de la Rosa‐Prieto, C., Úbeda‐Bañón, I., & Martínez-Marcos, A. (2011) · InTech eBooks · doi:10.5772/18169 · Cited by 4
“Somatostatin levels decline with aging (Lu et al., 2004) and are further reduced in AD (Davies et al., 1980).”
BackgroundBurgos‐Ramos, E., Puebla‐Jiménez, L., Hernández‐Pinto, A. M., & Arilla, E. (2009) · Neuroendocrinology · doi:10.1159/000194657 · Cited by 3
“The SRIH concentration has been demonstrated consistently to be reduced in brain biopsies and postmortem cerebral cortex tissues of AD patients [”
BackgroundArvat, E., Giordano, R., Pellegrino, M., Lanfranco, F., Baldi, M., PICU, A., Bonelli, L., & Ghigo, E. (2006) · Elsevier eBooks · doi:10.1016/b978-012088484-1/50024-0 · Cited by 3
Neuronal Disorders: Studies of Animal Models and Human Diseases
Price, D. L., Sisodia, S. S., Koo, E. H., Muma, N. A., Kitt, C. A., Walker, L. C., Martin, L. J., Troncoso, J. C., Griffin, J. W., Hoffman, P. N., et al. (1990) · Toxicologic Pathology · doi:10.1177/019262339001800118 · Cited by 3
Pathology, Neurobiology, and Animal Models of Alzheimer's Disease
Sisodia, S. S., Price, D. D., Crain, B. J., & Troncoso, J. C. (1996) · Informa Healthcare eBooks · doi:10.1201/9781420048407.ch12 · Cited by 3
Cerebrospinal Fluid Neurochemical Markers in Alzheimer’s Disease
Atack, J. R. (1989) · Springer eBooks · doi:10.1007/978-3-642-46690-8_1 · Cited by 3
Chapter 6. Cotransmitters in the CNS
Pazoles, C. J., & Ives, J. L. (1985) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61032-5 · Cited by 3
Prolonged exposure to increases intracellular and secreted somatostatin in rat cortical cells
Ham, J., RICKARDS, C. R., & Scanlon, M. F. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90476-a · Cited by 3
Strategies for Treating Alzheimer’s Disease and Age-Associated Memory Impairment
Crook, T. H. (1989) · Springer eBooks · doi:10.1007/978-3-642-46658-8_18 · Cited by 3
Westenberg, H. G. M., & Verhoeven, W. M. A. (1988) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930030408 · Cited by 3
“, 1983) and a decrease in somatostatin-like immunoreactivity (Davis et al., 1980; Francis and Bowen, 1985).”
BackgroundBarrios, V., Puebla, L., Rodríguez-Sánchez, M. N., & Arilla, E. (1993) · Regulatory Peptides · doi:10.1016/0167-0115(93)90164-4 · Cited by 3
Alzheimer's disease: clinical, neuropathologic, neuropsychologic, and brain metabolic findings
Cutler, N. R., & Narang, P. K. (1986) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331758600100105 · Cited by 3
Prange, A. J., & Nemeroff, C. B. (1982) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60486-8 · Cited by 3
Animal Models of Alzheimer’s Disease
Dunnett, S. B. (1994) · Springer eBooks · doi:10.1007/978-1-4615-6805-6_14 · Cited by 3
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex
Hirsch, S. R., & de Belleroche, J. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00587-0 · Cited by 3
Neurotransmitter Interactions and Responsivity to Cholinomimetic Agents
Haroutunian, V. H., Santucci, A., & Davis, K. L. (1992) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4615-9843-5_8 · Cited by 3
Schettini, G., Florio, T., Ventra, C., & Postiglione, A. (1990) · Springer eBooks · doi:10.1007/978-3-642-84224-5_12 · Cited by 3
Cognitive Enhancers in Alzheimer's Disease
Cutler, N. R., & Narang, P. K. (1989) · Clinical Research Practices and Drug Regulatory Affairs · doi:10.3109/10601338909020561 · Cited by 2
Kim, I., Griffith, K. R., Brockway, D. F., Crowley, N. A., & Medina, S. H. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139466 · Cited by 2
Seq-ing mechanisms behind types of Alzheimer’s disease
Chen, Y., & Ulrich, J. D. (2024) · Neuron · doi:10.1016/j.neuron.2024.04.030 · Cited by 2
Solano-Aguilar, G. I., Matuszek, G., Matthan, N. R., Lichtenstein, A. H., Wang, X., Lakshman, S., Barger, K., Urban, J. F., Molokin, A., Bennett, R. E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-81321-1 · Cited by 2
Anti-amyloid β hydrophobic peptides in Alzheimer’s disease: biomarkers and therapeutic potential
Gutiérrez‐Merino, C. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100672 · Cited by 2
Presynaptic Receptors Modulating Transmitter Release: Physiological and Pharmacological Aspects
Raiteri, M., Marchi, M., Maura, G., Bonanno, G., Pittaluga, A., Paudice, P., Gemignani, A., Pende, M., & Drago, C. (1992) · Pharmacochemistry library · doi:10.1016/b978-0-444-88931-7.50011-6 · Cited by 2
Simpkins, J. W., Rahimy, M. H., & Bodor, N. S. (1989) · Advances in behavioral biology · doi:10.1007/978-1-4684-5727-8_18 · Cited by 2
Perez-Oso, E., & Arilla, E. (1993) · Brain Research Bulletin · doi:10.1016/0361-9230(93)90023-5 · Cited by 2
A rationale for studying the transmissibility of Alzheimer's disease
Deutsch, S. I., Mohs, R. C., & Davis, K. L. (1982) · Neurobiology of Aging · doi:10.1016/0197-4580(82)90011-2 · Cited by 2
Gutiérrez‐Merino, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813846 · Cited by 4
“Reduction in SST immunoreactivity in the cerebral cortex of AD patients [144].”
Neuropeptide Y‐Cholinergic Interactions in Neocortical Tissue
Poulakos, J. J., Meyer, E. M., Pruysers, C. R., & Millard, W. J. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb48933.x · Cited by 2
The kindling-activated neuronal network: Recruitment of somatostatin-synthesizing neurons
Pretel, S., Applegate, C. D., & Piekut, D. T. (1996) · Brain Research Bulletin · doi:10.1016/s0361-9230(96)00194-3 · Cited by 2
Álvaro-Alonso, I., Prieto, J. C., & Arilla, E. (1993) · Psychopharmacology · doi:10.1007/bf02246957 · Cited by 2
“A profound deficit in cholinergic innervation in the cerebral cortex and hippocampus of patients with dementia from Alzheimer's disease (Hardy et al. 1985) coexists with a widespread reduction in cortical somatostatin-like immunoreactivity (SLI) ( Davies et al. 1980 ).”
BackgroundCLINICAL CONFERENCES*: Dementia: Clinical and Basic Science Aspects
Hamill, R. W., & Buell, S. J. (1982) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1982.tb03370.x · Cited by 2
Somatostatin expression in TS16 mouse brain cultures
Corsi, P., Forloni, G., Troia, M., Lettini, T., & Coyle, J. T. (1998) · Journal of Molecular Neuroscience · doi:10.1007/bf02737121 · Cited by 2
Transmitter deficits in Alzheimer's disease
Rossor, M. N. (1985) · Neurochemistry International · doi:10.1016/0197-0186(85)90052-x · Cited by 2
Kaneda, H., & Maeda, K. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91190-8 · Cited by 2
A DAY HOSPITAL FOR COGNITIVE DISORDERS: EXPERIENCE OF THE FIRST YEAR OF ACTIVITY
Geroldi, C., Frisoni, G. B., Zanetti, O. O., Bianchetti, A., & Trabucchi, M. (1996) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199610)11:10<915::aid-gps411>3.0.co;2-h · Cited by 1
Herrera‐Marschitz, M., & Ungerstedt, U. (1990) · Advances in behavioral biology · doi:10.1007/978-1-4684-5844-2_90 · Cited by 2
Sato, H., Mizukawa, K., Ogawa, N., Asanuma, M., Takayama, H., & Ota, Z. (1991) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.28.18 · Cited by 2
Potential Therapeutic Use of Growth Hormone in the Metabolic Treatment of Alzheimer’s Disease.
Millard, W. J. (1992) · Advances in behavioral biology · doi:10.1007/978-1-4615-3432-7_31 · Cited by 2
Perspective of Neurochemistry in Neurological Disorders
Tang, L. (1995) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1857-0_1 · Cited by 2
Knowles, S. J., Holter, M. C., Li, G., Bjorklund, G. R., Rees, K. P., Martinez-Fuentes, J. S., Nishimura, K. J., Afshari, A. E., Fry, N., Stafford, A. M., et al. (2023) · doi:10.7554/elife.88313.1 · Cited by 2
Knowles, S. J., Holter, M. C., Li, G., Bjorklund, G. R., Rees, K. P., Martinez-Fuentes, J. S., Nishimura, K. J., Afshari, A. E., Fry, N., Stafford, A. M., et al. (2023) · doi:10.7554/elife.88313 · Cited by 2
Blumenfeld, J. R., Li, Y., Kim, M. J., Yip, O., Yao, L., Leon, S. D., Fulthorpe, R., Shostak, D. M., Platow, Z., Suan, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690488 · Cited by 3
Varghese, R., Digholkar, G., Deshpande, A., & Kumar, D. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815136142123010013 · Cited by 1
Riekkinen, P. J., Helkala, E., Jolkkonen, J., Riekkinen, P. J., & Soininen, H. S. (1990) · Drug Development Research · doi:10.1002/ddr.430200404 · Cited by 1
Altered GABA function in Major Depression
French, B. J., Seney, M. L., & Sibille, E. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1056-4_13 · Cited by 2
Changes in neuropeptide levels after brain damage in rats
Ćulić, M., Šaponjić, J., Todorović, V., Janković, B., Udović, S., Peković, S., Stojiljković, M., Ratković, M., Nikolić, A., & Rakić, L. (1995) · Neuropeptides · doi:10.1016/0143-4179(95)90057-8 · Cited by 1
Therapeutic applications of neural transplant technology
Rogers, J., Zornetzer, S. F., & Simon, M. L. (1985) · Neurobiology of Aging · doi:10.1016/0197-4580(85)90043-0 · Cited by 1
Neuropeptides in Alzheimer's disease: Somatostatin, Neuropeptide Y, and Galanin
Cutler, N. R. (1990) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331759000500103 · Cited by 1
Novel Somatostatin Receptor Subtype‐4 Agonist Mitigates Microglia Inflammatory Activation
Silwal, A., Mobayen, S., Crider, A. M., Neumann, W. L., House, A., Umbaugh, D. S., Bhandari, S., Sandoval, K. E., & WITT, K. A. (2019) · The FASEB Journal · doi:10.1096/fasebj.2019.33.1_supplement.501.3 · Cited by 1
Alzheimer’s Research Goes Deeper: Ultrastructural Electron Microscopy Studies
Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_4 · Cited by 1
Growdon, J. H., Corkin, S., Buonanno, F. S., Davis, K. L., Huff, F. J., Beal, M. F., & Kramer, C. (1986) · Advances in behavioral biology · doi:10.1007/978-1-4613-2179-8_25 · Cited by 1
Neuropeptide Abnormalities in Alzheimer’s and Huntington’s Diseases
Martin, J. B., & Beal, M. F. (1988) · Springer eBooks · doi:10.1007/978-1-4613-1721-0_14 · Cited by 1
Opioid and non-opioid activities of the dynorphins
Marinova, Z. (2005) · Figshare · Cited by 3
Neuropeptides in Central Movement Disorders of Man
Weindl, A., Unger, J. W., Schwartzberg, M., Triepel, J., Lange, W., & Struppler, A. (1987) · Advances in applied neurological sciences · doi:10.1007/978-3-642-71540-2_27 · Cited by 1
SOMATOSTATIN AND HEAT SENSITIVITY IN MULTIPLE SCLEROSIS
Post, R. M., & Rubinow, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90330-2 · Cited by 1
Diminution of preprosomatostatin-mRNA in cerebral cortex of the aged rat
Nilsson, L. N. G., Winblad, B. G., & Bergström, L. (1995) · Neurochemistry International · doi:10.1016/0197-0186(95)80006-7 · Cited by 1
Effects of somatostatin-14 on active avoidance behavior in female rats
Masirevic-Draskovic, G., Terzić, M., Nesic, D., Stevanovic, D., Milošević, V., Starcevic, V. P., & Severs, W. B. (2007) · Archives of Biological Sciences · doi:10.2298/abs0704055m · Cited by 1
Strittmatter, M., Cramer, H., Reuner, C., Strubel, D., & Kuntzmann, F. (1990) · Key topics in brain research · doi:10.1007/978-3-7091-3396-5_35 · Cited by 1
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.